Montreal’s MédiMabs to distribute reagent antibodies to international market
July 17, 2017 – Toronto, ON, Canada – The Centre for the Commercialization of Antibodies and Biologics (CCAB) and MédiMabs Antibodies have signed an agreement for the distribution of CCAB’s reagent antibodies. The agreement marks the launch of a new business segment for CCAB and allows MédiMabs to expand its portfolio to include human synthetic antibodies.
“CCAB is enthusiastic to be working with MédiMabs and benefit from its experience in antibody distribution,” Robert Verhagen, CEO of CCAB said. “This collaboration will not only help both organizations expand their businesses, it will benefit the research community by offering a unique set of reagent antibodies that is currently limited in the market.”
Through CCAB’s rigorous selection process, the company has developed a portfolio of monoclonal research-grade antibodies against an array of human proteins involved in various diseases such as cancer and autoimmune disorders. The antibodies exhibit competitive properties for reagent use primarily by Flow Cytometry and ELISA applications.
“MédiMabs is looking forward to working with CCAB since our organizations have great synergy and compatible technologies,” Martin Wong, MédiMabs Chairman said. “We are confident that this partnership will be a win-win for both companies and together we can deliver new and unique antibodies to life sciences researchers.”
MédiMabs will distribute the CCAB reagent antibodies to an international market. They are now available on MédiMabs’ new website.
The Centre for the Commercialization of Antibodies and Biologics is a not-for-profit organization providing expertise in product and business development to rapidly translate inventions toward achieving a real impact within the healthcare system and the broader scientific research community. CCAB combines in-house capacities in the development of therapeutics, diagnostics and reagents, with the support of start-up companies in these areas.
MédiMabs is a privately held Canadian company that specializes in the development of custom antibodies, the acquisition of licenses and the commercialization of research-grade antibodies as well as related services to biomedical researchers, biotechnology and phamaceutical companies worldwide. MédiMabs also has R&D programs to generate novel research, therapeutic and diagnostic antibodies.
Social media links:
For more information contact:
Karen Ramlall | Manager, Communications | CCAB | firstname.lastname@example.org
Tags: human monoclonal antibody, reagent antibodies, research-grade antibody